Literature DB >> 1885783

Chylomicron-retinyl palmitate clearance in type I hyperlipidemic families.

D L Sprecher1, S L Knauer, D M Black, L A Kaplan, A A Akeson, M Dusing, D Lattier, E A Stein, M Rymaszewski, D A Wiginton.   

Abstract

Our primary aim was to determine the extent to which intraplasmic retinyl palmitate (RP) transfers to other lipoprotein particles when chylomicron remnants are not produced and/or the plasma RP residence time is increased. The study was conducted on three familial type I hyperlipoproteinemic patients, four lipoprotein lipase (LpL)-deficient heterozygotes, and three controls on a metabolic research unit. To each subject, a fat load was administered containing 16% of total daily calories in type I patients, 40% in heterozygotes and controls, plus 60,000 U/m2 vitamin A. Triglyceride (TG) and RP levels were evaluated in chylomicron and nonchylomicron fractions. Delay in the clearance of chylomicron fraction RP and the marked deficiency in nonchylomicron-RP (presumed lack of remnant production) in all three type I patients suggests that RP does not demonstrate significant intraplasmic transfer from chylomicrons to existent apolipoprotein B100 particles. In contrast to noncoincident TG and RP peaking in the normal subject, heterozygotes were found to demonstrate coincident plasma TG and RP curves, which is consistent with a common catabolic pathway for both TG and RP and inconsistent with intraplasmic RP transfer. This corroborates reports on compromised chylomicron clearance in heterozygotes. We conclude that RP is an appropriate representative marker for intestinally derived particles in LpL-deficient or partially deficient individuals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885783      PMCID: PMC295501          DOI: 10.1172/JCI115402

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

1.  Diet and HDL metabolism: high carbohydrate vs. high fat diets.

Authors:  R L Jackson; M T Yates; C A McNerney; M L Kashyap
Journal:  Adv Exp Med Biol       Date:  1987       Impact factor: 2.622

2.  Defective enzyme protein in lipoprotein lipase deficiency.

Authors:  J H Auwerx; S P Babirak; W Y Fujimoto; P H Iverius; J D Brunzell
Journal:  Eur J Clin Invest       Date:  1989-10       Impact factor: 4.686

3.  Two-dimensional electrophoresis of human plasma apolipoproteins.

Authors:  D L Sprecher; L Taam; H B Brewer
Journal:  Clin Chem       Date:  1984-12       Impact factor: 8.327

4.  Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B.

Authors:  S G Young; R S Smith; D M Hogle; L K Curtiss; J L Witztum
Journal:  Clin Chem       Date:  1986-08       Impact factor: 8.327

5.  Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

6.  Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.

Authors:  M S Weintraub; S Eisenberg; J L Breslow
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

7.  An enzyme-linked immunoassay for lipoprotein lipase.

Authors:  J W Goers; M E Pedersen; P A Kern; J Ong; M C Schotz
Journal:  Anal Biochem       Date:  1987-10       Impact factor: 3.365

8.  Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey.

Authors:  I J Goldberg; N A Le; H N Ginsberg; R M Krauss; F T Lindgren
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

Review 9.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

Authors:  R W Mahley
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

10.  Plasma clearance of chylomicrons labeled with retinyl palmitate in healthy human subjects.

Authors:  F Berr; F Kern
Journal:  J Lipid Res       Date:  1984-08       Impact factor: 5.922

View more
  6 in total

1.  Assessment of French patients with LPL deficiency for French Canadian mutations.

Authors:  L Foubert; J L De Gennes; J P Lagarde; E Ehrenborg; A Raisonnier; J P Girardet; M R Hayden; P Benlian
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

2.  Lipoprotein lipase deficiency is associated with elevated acylation stimulating protein plasma levels.

Authors:  Sabina Paglialunga; Pierre Julien; Youssef Tahiri; Francois Cadelis; Jean Bergeron; Daniel Gaudet; Katherine Cianflone
Journal:  J Lipid Res       Date:  2009-02-23       Impact factor: 5.922

Review 3.  Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk.

Authors:  Jila Kaberi Otarod; Ira J Goldberg
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

4.  Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities.

Authors:  G Miesenböck; B Hölzl; B Föger; E Brandstätter; B Paulweber; F Sandhofer; J R Patsch
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

Review 5.  Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.

Authors:  Alan Chait; Henry N Ginsberg; Tomas Vaisar; Jay W Heinecke; Ira J Goldberg; Karin E Bornfeldt
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

Review 6.  Exercise and dietary-mediated reductions in postprandial lipemia.

Authors:  Eric P Plaisance; Gordon Fisher
Journal:  J Nutr Metab       Date:  2014-06-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.